Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX
-
Wembanyama wins NBA defensive player of the year
-
'The Devil Wears Prada 2' stars reunite for glamorous premiere
-
El Salvador holds mass trial of nearly 500 alleged gang members
-
Apple's Tim Cook to step down as CEO in September
-
West Ham's draw at Palace relegates Wolves, piles pressure on Spurs
-
Canadian tourist killed in Mexico archaeological site shooting
-
Wolves relegated from Premier League
-
Oil jumps on Hormuz tensions, stocks mostly retreat
-
Colombian environmental activist honored amid threats and exile
-
Gun battle traps more than 200 tourists at Rio viewpoint
-
Alcaraz may skip French Open rather than rush injury comeback
-
Top US court to hear case of Catholic schools excluded from state funding
-
Trump Fed chair pick to vow interest rate independence at key hearing
-
EU to host Taliban officials for talks on deporting Afghans
-
Blue Origin probing rocket's failure to deliver satellite
-
Pope blasts 'exploitation' as he wraps up tour of Angola
-
Wembanyama 'changing the game as we speak', says Nowitzki
-
Singer D4vd charged with murder after teen's body found in Tesla
-
Swiss football club turn down Kanye West concert approach
-
Leicester fairytale turns sour as relegation to third tier looms
-
Pope Leo blasts 'exploitation' as he wrap up tour of resource-rich Angola
-
Varma ton revives Mumbai's IPL hopes with win over Gujarat
-
Formula One makes rule changes after drivers' criticism
-
Singer D4vd charged with murder over teen's body found in Tesla
-
UK PM denies misleading MPs, says officials hid Mandelson info
-
Tit-for-tat blockades once again cripple traffic in Hormuz
-
Cafu says 2026 World Cup is perfect time for Brazil to win again
-
Erdogan vows new measures after deadly Turkey school shootings
-
Rose to take charge at Bournemouth after Iraola exit
-
Olympic status a massive 'boost' for squash says European champion Crouin
-
Kenyan double-double as Korir, Lokedi defend Boston Marathon crowns
-
Whale stranded on German coast swims off, gets stuck again
-
Iran pulling Hormuz 'lever' to maximum in US standoff
-
Argentine film and theater great Luis Brandoni dies at 86
-
French Open sensation Boisson returns to action after 'most difficult' spell
-
Desmond Morris: from 'Naked Ape' to watching 'Big Brother'
-
Rosenior says Chelsea owners supportive despite slump
-
Oil jumps on Hormuz tensions, stocks retreat
-
Romania legend Hagi eyes 'winning every game' on return as coach
-
Rana stars as Bangladesh down New Zealand to level ODI series at 1-1
-
Real Madrid coach Arbeloa launches stout defence of Mbappe
-
Pope Leo blasts 'exploitation' on visit to resource-rich Angola
-
Amy Winehouse's father loses suit against friends selling her clothes
-
Japan issues warning after 7.7-magnitude quake hits north
-
UniCredit woos Commerzbank shareholders in takeover battle
-
European stocks slide as oil jumps on Hormuz tensions
-
Amy Winehouse's dad loses suit against friends for selling clothes
-
Slovenian liberal Golob fails to form government
-
Elon Musk summoned over French X deepfake probe but presence unclear
-
Tsunami warning as major quake hits northern Japan, shakes Tokyo
Ablexis Announces Validation and Availability of AlivaMab(R) Mouse-NGX
Launching the most advanced transgenic animal platform for human antibody drug discovery
SAN DIEGO, CA / ACCESS Newswire / September 2, 2025 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab Mouse technology, today announced the launch of AlivaMab Mouse-NGX, a next-generation suite of advanced transgenic mice that expand both the number and human variable region diversity of antigen-specific antibodies while retaining their requisite drug-like properties.
"AlivaMab Mouse-NGX strains represent a major evolution of our platforms relative to earlier generations of AlivaMab Mouse, which already outperformed other transgenic models and have yielded at least 18 antibodies entered into clinical trials," said Larry Green, Ph.D., Chief Executive Officer of Ablexis. "Our validation tests confirm that AlivaMab Mouse-NGX strains produce up to six-times the number of antigen-specific antibodies while also exhibiting expansion of combinatorial and junctional diversity versus comparator platforms. AlivaMab Mouse-NGX strains set a new benchmark for success in B-cell- and NGS-based human antibody drug discovery," Dr. Green continued.
The AlivaMab Mouse platform is available for use in-house by Ablexis' licensees or exclusively for service provision through AlivaMab Biologics, including access on a license-free, milestone- and royalty-free basis.
About Ablexis, LLC
Ablexis, LLC creates and offers AlivaMab Mouse, a growing suite of unique, patented next generation transgenic mice, as a foundational platform for successful human antibody drug discovery and development. Dozens of companies, including 13 of the world's top 25 global pharmaceutical companies, public and private biotechnology companies, and other entities have licensed AlivaMab Mouse for their antibody drug discovery. Ablexis' sister company, AlivaMab Biologics provides an integrated antibody therapeutic discovery and engineering platform using the AlivaMab Mouse technologies. For more information, please contact us at [email protected].
###
Media Contact:
Maya Tanaka
[email protected]
SOURCE: Ablexis, LLC
View the original press release on ACCESS Newswire
P.Mathewson--AMWN
